

REMARKS

Applicant thanks the Examiner for taking the time to review each of the claimed peptides in Group I, and for acknowledging that polypeptides comprising SEQ ID NO: 1-23 and 26-31 are free of the art.

Applicant respectfully requests reconsideration of the present application in view of the foregoing amendments and in view of the reasons that follow. Following amendment, claims 1, 3-22 and 24-54 are currently pending in the application. Claims 1, 18-22, 26, 27, 31, 33, 39, 43 and 49 have been amended. Claim 2 and claim 23 have been cancelled. Claims 52-54 have been added. Claims 22-31, 34-38, and 46-51 have been withdrawn. Claims 1-21, 32-33, 39-45 were examined on the merits.

This amendment adds, changes and/or deletes claims in this application. A detailed listing of all claims that are, or were, in the application, irrespective of whether the claim(s) remain under examination in the application, is presented, with an appropriate defined status identifier. Support for the claim amendments can be found throughout the specification.

Applicant believes that the present application is now in condition for allowance, thus favorable reconsideration of the application as amended is respectfully requested.

I. Finalization of Restriction Requirement

Regarding the finalization of the restriction requirement in the Office Action, applicant reserves the right to rejoin the method claims of Group II upon the allowance of the claims of Group I pursuant to M.P.E.P. § 821.04. Applicant respectfully directs the Examiner's attention to § 821.04 of the M.P.E.P. which states, with respect to rejoinder,

However, if applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims which depend from or otherwise include all the limitations of the allowable product claim will be rejoined.

Where the application as originally filed discloses the product and the process for making and/or using the product, and only claims directed to the product are presented for examination, when a product claim is found allowable, applicant may present claims

directed to the process of making and/or using the patentable product by way of amendment pursuant to 37 C.F.R. 1.121. In view of the rejoinder procedure, and in order to expedite prosecution, applicants are encouraged to present such process claims, preferably as dependent claims, in the application at an early stage of prosecution. Process claims which depend from or otherwise include all the limitations of the patentably produce will be entered as a matter of right if the amendment is presented prior to final rejection or allowance.

In light of this section of the MPEP, certain claims of Group II, although presently withdrawn, have been amended to keep them in line with the amendments to the product claims. Applicant respectfully contends that the claims of Group II must be rejoined with the claims of Group I if the products of claim 1 should be found allowable. For this reason, applicant has not cancelled these claims from the present application.

II. Priority

Applicant acknowledges that claims 1 and 3-21 of the instant invention have been accorded a filing date of January 31, 2002. Nevertheless, applicant disagrees with the Examiner that claims 39-45 should not be able to claim priority to the provisional patent application. Therefore, applicant submits that claims 39-45 should be afforded a priority date of March 21, 2001, the filing date of Provisional Patent Appl. No.: 60/278,465.

III. Claims

A. Claim Objections

The Examiner objected to claims 32 and 33 for being dependent on a non-elected claim. Claims 32 and 33 have been withdrawn, rendering this objection moot. Therefore, applicant requests the Examiner withdraw the rejection.

B. Claim Rejections

i. 35 U.S.C. § 112

a. 35 U.S.C. § 112, second paragraph

The Office Action rejected claims 3-17, 21 and 39-45 under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Applicant respectfully traverse.

Claims 3-17 were rejected based on the Examiner's belief that "[i]t is unclear how claims 3-17 further limit claim 1." The Examiner further stated that it is unclear if the dependent claims "include SEQ ID NO: X and SEQ ID NO: Y having one or more conservative amino acid substitutions." Claim 1 has been amended so that it no longer allows for conservative amino acid substitutions. Therefore, it is clear that claims 3-17 currently only refer to the specific sequence claimed. In light of this, applicant submits that claims 3-17 are clear as written and requests that the rejection of claims 3-17 under 35 U.S.C. § 112, second paragraph, be withdrawn.

In the Office Action, claim 21 was rejected because the Examiner stated that "it is unclear how 'consisting essentially of' differs from comprising." Applicant is confused by the Examiner's rejection. M.P.E.P. § 2111.03 states that "comprising ... does not exclude additional, unrecited elements or methods" and that "'consisting essentially of' limits the scope of a claim to the specified materials or steps and 'those that do not materially affect the basic and novel characteristic(s)' of the claimed invention." Emphasis in original. M.P.E.P. § 2111.03 clearly states that "a 'consisting essentially of' claim occupies a middle ground between closed claims that are written in a 'consisting of' format and fully open claims that are drafted in a 'comprising' format." Because the two transitional phrases are recognized as distinct by the M.P.E.P., they should be recognized as distinct by the Examiner. Applicant thereby requests the Examiner withdraw the 35 U.S.C. § 112, second paragraph rejection as applied to claim 21.

Claim 39 was rejected for the inclusion of the phrase "immunogenic molecule," which the Examiner states "cannot be determined without reference to the host experiencing the immunogenicity." Claim 39 has been amended to remove the phrase "immunogenic molecule" and replace it with the phrase "tumor-associated antigen." Support for this amendment can be found in paragraphs [0016] and [0101]. The Examiner stated that for purposes of examination,

the claim was read with the proviso that the peptide “does not bind to a cancer-associated antigen on the surface of the cell.” Applicant believes the amendment overcomes the Examiner’s rejection to Claim 39 and respectfully requests that claim 39, as amended, be allowed to issue.

In the Office Action, claim 43 was rejected because the recitation of “accessory molecule” in claim 43 lacks antecedent basis and because the Office Action stated that the “difference between a ‘tag molecule’ and an ‘identification molecule’” could not be discerned. First, the Examiner was correct to read claim 43 as dependent upon claim 42. Claim 43 has been amended to correctly depend from claim 42 and to remove the phrase “identification molecule.” In light of the amendments to claim 43, applicant respectfully requests the rejection be withdrawn and the claim be allowed to issue.

b. 35 U.S.C. § 112, first paragraph

Claims 1, 21 and 39-45 were rejected in the Office Action under 35 U.S.C. § 112, first paragraph as failing to comply with the written description requirement. The Office Action states that the claims contain “subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor, at the time the application was filed, had possession of the claimed invention.” The Examiner states that the claimed genus is “not limited by functional attributes of the individual species. Thus, the genus is highly variant encompassing proteins and peptides which have no amino acid sequence similarity to the described SEQ ID NO: 1-23 or 26-31 and which have functional characteristics which differ from those of SEQ ID NO.: 1-23 or 26-31.” First, claims 1 and 21 have been amended so that they no longer cover amino acids having one or more conservative amino acid substitutions. Therefore, in relation to claims 1 and 21, this rejection has been rendered moot.

However, new claims 52 and 53 provide for an isolated polypeptide comprising a sequence selected from one of SEQ ID NOS.: 1-23 having one or more conservative amino acid substitutions; or SEQ ID NOS.: 26-31 having one or more conservative amino acid substitutions, wherein the one or more conservative amino acid substitutions do not decrease the biological activity of the isolated polypeptide as compared to a non-conservative amino acid substituted polypeptide from which an amino acid substituted polypeptide derives. With the addition of the functional limitation to claim 52, claim 52 clearly describes the claimed variant genus. Support

for this functional limitation can be found in the specification as originally filed at paragraph [0052], which states that “[g]uidance in determining which amino acid residues can be substituted, inserted, or deleted without abolishing biological activity can be found using computer programs well known in the art, for example LASERGENE software (DNASTAR Inc., Madison, Wisconsin).” Because one of skill in the art would reasonably conclude that the applicant was in possession of the genus claimed in amended claims 1 and 21 and new claim 52 at the time of filing, the 35 U.S.C. § 112, first paragraph rejection should be withdrawn and the claims should be allowed to issue.

The Examiner rejected claims 39-45 under 35 U.S.C. § 112 as encompassing a highly variant genus of proteins, “which do not have common structural or functional attributes.” Claim 39 has been amended to provide for an isolated polypeptide that “binds preferentially to a surface of a cancerous blood cell and does not bind to the surface of a non-cancerous blood cell or binds preferentially to a surface of a non-cancerous blood cell and does not bind to the surface of a cancerous blood cell with the proviso that the peptide does not bind to a tumor-specific antigen.” The claim as amended to include the functional limitation can be supported by the specification as filed, namely paragraphs [0020], [0025] and [0047]. Because all peptides must bind preferentially either to a surface of a cancerous blood cell and not to the surface of a non-cancerous blood cell or to a surface of a non-cancerous blood cell and not to the surface of a cancerous blood cell to be included in the genus, claim 39 satisfies the requirements of 35 U.S.C. § 112, first paragraph. In light of this, applicant requests the Examiner withdraw the rejection to claim 39 and allow the claim to issue. Because claims 40-45 either depend directly or indirectly from claim 39, these claims also satisfy 35 U.S.C. § 112, first paragraph and should be allowed to issue.

ii. 35 U.S.C. § 102

The Examiner rejected claims 39, 40, 44, and 45 under 35 U.S.C. 102(b) as anticipated by the abstract of Nakaya *et al.* (Biochemistry International, 1985, Vol. 10, pp. 619-626) or the abstract of Ajinomoto (EP 210,461). Applicant respectfully traverses. A *prima facie* case of anticipation under 35 U.S.C. § 102 requires that a single reference teach each and every element of the claimed invention. M.P.E.P. § 2131. The present invention as defined, e.g., by

amended claim 39, distinguishes over the cited references by reciting “an isolated peptide comprising a binding region which binds preferentially either to a surface of a cancerous blood cell or to a surface of a non-cancerous blood cell with the proviso that the peptide does not bind to a tumor-specific antigen on the surface of the cancerous or non-cancerous blood cell.” As neither Nakaya *et al.* or Ajinomoto teach this element of the claimed invention, applicant respectfully asserts that a *prima facie* case of anticipation based on these two references has not been established.

Nakaya *et al.* disclose a differentiation factor produced in culture medium, which can be isolated from the conditioned medium. Ajinomoto simply teach a differentiation factor capable of differentiating and maturing mouse leukemia cells into normal cells. The factors disclosed in these two references are clearly different than a peptide that can preferentially bind to a surface of a cancerous blood cell or to a surface of a non-cancerous blood cell. One of skill in the art can clearly foresee the advantages that exist with a peptide capable of specifically binding to a certain cell population. For example, as stated in the specification, binding to a cell surface allows the peptides of the present invention to be used for “separating specific cell types from mixed cell populations (leukemic or normal) using solid state methods (columns or panning), flow cytometry or magnetic beads.” Specification paragraph [0060]. Unlike the peptides of the present invention, the differentiation factors disclosed in Nakaya *et al.* and Ajinomoto have not been shown to preferentially bind to the surface of a cancerous blood cell and not to the surface of a non-cancerous cell or preferentially bind to the surface of a non-cancerous blood cell and not to the surface of a cancerous blood cell. Because the two references cited by the Examiner do not teach or suggest every element of presently amended claim 39, they cannot anticipate the claim. As claims 40, 44 and 45 depend from claim 39, the Nakaya *et al.* and Anjinomoto references also fail to anticipate these claims. Because the Examiner has failed to make a *prima facie* case of anticipation, applicant respectfully requests the rejection be withdrawn and claims 39, 40, 44 and 45 be allowed to issue.

In the Office Action, claims 39, 40 and 45 were rejected under 35 U.S.C. § 102(b) as anticipated by Steube *et al.* (Leukemia, 1992, vol. 6, pp. 1048-1053). Applicant respectfully submits that the Examiner is reading more into Stuebe *et al.* than is warranted from the short

abstract provided with the present Office Action. Applicant respectfully submits that the Examiner has failed to make out a *prima facie* case of anticipation because Steube *et al.* fails to teach or disclose every element of the claimed invention. Applicant agrees with the Examiner that the abstract of Steube *et al.* teaches that dolastatin 10 and dolastatin 15 can inhibit the growth of leukemia cells while remaining non-cytotoxic to dividing cells or resting cells. However, at no point does the abstract of Stuebe *et al.* teach or disclose a peptide that preferentially binds to a surface of a cancerous blood cell and not to the surface of a non-cancerous blood cell or preferentially binds to a surface of a non-cancerous blood cell and not to the surface of a cancerous blood cell, with the proviso that the peptide does not bind to a tumor-associated antigen. As demonstrated by the enclosed Verdier-Pinard article, it appears that dolastatin 10 enters cells primarily through passive diffusion and not through cell-surface binding (Verdier-Pinard *et al.*, Molecular Pharmacology, 2000, Vol. 57, pp 180-187). Thus, the peptides disclosed by Stuebe *et al.* do not accomplish the inhibition of leukemia cells through preferentially binding to the surface of a cancerous blood cell and not to the surface of a non-cancerous blood cell or preferentially binding to the surface of a non-cancerous blood cell and not to the surface of a cancerous blood cell. Because Stuebe *et al.* fail to disclose or teach every element of claim 39, a *prima facie* case of anticipation has not been achieved. Applicant respectfully requests the Examiner withdraw the 35 U.S.C. § 102(b) rejection and allow claim 39 to issue. As claim 40 and 45 both depend from claim 39, these claims should also be allowed to issue.

In the Office Action, claims 39, 40, 41, and 45 were rejected under 35 U.S.C. § 102(b) as anticipated by Vidovic and Toral (Cancer Letters, 1998, Vol. 128, pp 127-135). Applicant respectfully traverses. Vidovic and Toral disclose a monoclonal antibody which binds to HLA-DR and induces selective apoptosis in malignant B-cells. The Examiner states that “it is noted that the HLA-DR is not a cancer associated antigen, and would not be expected to be immunogenic in the subject in which the malignant B cells originated or a syngenic individual.” However, in the situations described by the Examiner, the monoclonal antibody would not be expected to participate in cellular binding. Because claim 39 requires that the peptide preferentially bind to a cell surface, while not binding to a tumor-associated antigen, the antibody

of Vidovic and Toral does not disclose or teach every limitation of the claim. Therefore, applicant respectfully requests that the Examiner withdraw the rejection of claim 39. Because claims 40, 41, and 45 depend directly or indirectly from claim 39, the 35 U.S.C. § 102(b) rejection of these claims should be withdrawn as well.

Claims 1-5, 7-17 and 21 were all rejected under 35 U.S.C. § 102(b) as anticipated by various STN database entries. The Examiner bases her anticipatory argument on the fact that the original claims disclosing the sequences of the present invention provided for the substitution of one or more amino acids without any functional limitation. Applicant respectfully submits that this argument has been rendered moot. First, claim 1 and claim 21 have been amended to provide for only the specific sequences listed. Thus, because none of the database entries submitted by the Examiner exactly match the sequences of the present invention, these entries cannot anticipate claims 1-5, 7-17, and 21. Nor do the database entries anticipate newly added claims 52 or 53. Claim 52 provides for an isolated polypeptide comprising a sequence selected from one of SEQ ID NOS.: 1-23 having one or more conservative amino acid substitutions; or SEQ ID NOS.: 26-31 having one or more conservative amino acid substitutions, wherein the one or more conservative amino acid substitutions do not decrease the biological activity of the isolated polypeptide as compared to a non-conservative amino acid substituted polypeptide. In order to anticipate claim 52, the STN sequences cited by the Examiner must not decrease the biological activity of the substituted peptides as compared to the peptides from which they derive. Because none of the STN database entries cited by the Examiner teach or suggest a peptide that does not have decreased biological activity as compared to the peptide in the current specification from which it could be derived, the Examiner has not made out a *prima facie* case of anticipation with regard to any of the claims currently pending in the application. For this reason, applicant respectfully requests the Examiner withdraw the 35 U.S.C. § 102(b) rejection and allow all of the currently pending claims to issue.

CONCLUSION

In light of the above amendments and arguments, applicant respectfully submits that the currently pending claims are in condition for allowance. The Examiner is invited to

USSN 10/062,587

contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application.

Respectfully submitted,

Date October 14, 2004

FOLEY & LARDNER LLP
Customer Number: 23524
Telephone: (608) 258-4277
Facsimile: (608) 258-4258

By Kathryn E. Cox

Kathryn E. Cox
Attorney for Applicant
Registration No. 55,089

Sustained Intracellular Retention of Dolastatin 10 Causes Its Potent Antimitotic Activity

PASCAL VERDIER-PINARD, JOHN A. KEPLER, GEORGE R. PETTIT, and ERNEST HAMEL

Laboratory of Drug Discovery Research and Development, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick Cancer Research and Development Center, Frederick, Maryland (P.V.-P., E.H.); Research Triangle Institute, Research Triangle Park, North Carolina (J.A.K.); and Cancer Research Institute and Department of Chemistry, Arizona State University, Tempe, Arizona (G.R.P.)

Received May 3, 1999; accepted October 4, 1999

This paper is available online at <http://www.molpharm.org>

ABSTRACT

Dolastatin 10 is a highly cytotoxic antimitotic peptide in phase II clinical trials. Its cytotoxicity has been as much as 50-fold greater than that of vinblastine, despite quantitatively similar effects of the two drugs on tubulin polymerization. We compared uptake and efflux of radiolabeled dolastatin 10 and vinblastine in human Burkitt lymphoma CA46 cells to gain an understanding of the greater cytotoxicity of the peptide. In the Burkitt cells, dolastatin 10 was 20-fold more cytotoxic than vinblastine (IC_{50} values, 50 pM and 1.0 nM). When drug uptake at 24 h was compared at IC_{50} values of the two drugs, the intracellular concentrations were almost identical (50–100 nM). The accumulation factor observed for dolastatin 10 was 900 to 1800 versus 60 to 100 for vinblastine. The two drugs showed very divergent uptake kinetics, however. Vinblastine and dola-

statin 10 reached maximum intracellular concentrations after 20 min and 6 h, respectively. Depletion of cellular ATP content did not alter the uptake of either drug, indicating passive uptake of both. When drug-preloaded cells were transferred to drug-free medium, there was no loss of dolastatin 10 for at least 2 h, whereas vinblastine exited the cells rapidly (approximate intracellular half-life, 10 min), with less than 10% of the initial drug remaining in the cells after the 2-h incubation. The potency of dolastatin 10 probably derives from its tenacious binding to tubulin, a property that in cells becomes translated into prolonged intracellular retention of the drug. Optimal clinical use of dolastatin 10 may require administration by infusion rather than by bolus.

Dolastatin 10 is a potently cytotoxic peptide, with four of its five subunits derived from modified amino acids. It was originally isolated from the sea hare *Dolabella auricularia* (Pettit et al., 1987), a shell-less mollusk, but it was subsequently totally synthesized (Pettit et al., 1989). Dolastatin 10 causes the accumulation of cells arrested in mitosis and the disappearance of cellular microtubules (Bai et al., 1990b, 1992). The apparent target is the protein tubulin, the major component of microtubules. Characteristics of its interaction with tubulin include a potent inhibition of assembly (IC_{50} value, 1.2 μ M), noncompetitive inhibition of the binding of vinblastine to tubulin, and inhibition of nucleotide exchange (Bai et al., 1990a,b). Studies with [3 H]dolastatin 10 showed tight binding of the peptide to tubulin, but attempts to demonstrate formation of a tubulin-dolastatin 10 complex were unsuccessful. The smallest distinct species at low drug concentrations seemed to contain two $\alpha\beta$ -tubulin molecules and probably two dolastatin 10 molecules. At higher drug concentrations, massive polymers of aberrant morphology (probably tightly coiled spirals) form (Bai et al., 1995).

Dolastatin 10 inhibits the growth of various cancer cell lines at subnanomolar concentrations (Pettit et al., 1987; Bai

et al., 1990b; Beckwith et al., 1993; Turner et al., 1998), and the drug is active against human sarcoma, melanoma, and ovarian xenografts in nude mice (Pettit et al., 1987; Waud et al., 1993; Turner et al., 1998). In phase I studies in human subjects, the dose-limiting toxicity of dolastatin 10 was against bone marrow (Bagniewski et al., 1997), and the drug is currently in phase II clinical trials.

In our previous comparative studies of dolastatin 10 and vinblastine, we found the drugs had similar potencies as inhibitors of tubulin assembly, but the peptide was 20- to 50-fold more potent than vinblastine as an inhibitor of cell growth. The experiments described in this study were undertaken to gain insight into possible reasons for this difference. The most obvious possibility is a major difference in cellular accumulation of the two drugs.

Vinblastine and other vinca alkaloids have been shown to accumulate in cells (Lengsfeld et al., 1982; Gout et al., 1984; Ferguson and Cass, 1985; Jordan et al., 1991; Van Belle et al., 1991; Pierre et al., 1992; Singer and Himes, 1992; Breier et al., 1994; Dhamodharan et al., 1995; El Hafny et al., 1997), and studies with both vincristine (Breier et al., 1994) and vinblastine (Ferguson and Cass, 1985; Van Belle et al., 1991)

ABBREVIATIONS: p-gp 170, P-glycoprotein p170 (the multidrug transporter protein); MDR, multidrug resistant.

have indicated that accumulation of these drugs is by passive diffusion. Singer and Himes (1992) did note a close correlation among vinca alkaloids between efficiency of drug accumulation and degree of cytotoxicity. Moreover, Singer and Himes (1992) extrapolated their data to the IC_{50} values, concluding that at these initial extracellular concentrations the intracellular drug concentrations should be far lower than the total cellular tubulin concentration.

Our strategy was to directly examine drug effects primarily at the IC_{50} values. We have thus compared uptake and accumulation of [3 H]vinblastine and [3 H]dolastatin 10 at equitoxic concentrations. Efflux studies, however, were performed at the IC_{50} value for vinblastine. We found a good correlation between drug potency and the extent of intracellular drug accumulation. Thus, a substantially higher proportion of dolastatin 10 compared with vinblastine accumulates in cells. This results primarily from apparent entrapment of the peptide within cells, whereas substantial efflux of vinblastine occurs.

Materials and Methods

Materials. [3 H]dolastatin 10 (5.4 Ci/mmol) was prepared as described previously (Bai et al., 1995), and [3 H]vinblastine (15.5 Ci/mmol) was obtained from Amersham (Arlington Heights, IL). The methanol solvent for both drugs was removed by evaporation at room temperature under a gentle stream of air, and the residues were dissolved in dimethyl sulfoxide (stock solutions at 10 μ M). Monoclonal antibody C219 against P-glycoprotein p170 (p-gp 170) was generously provided by Dr. M. S. Poruchynsky, National Cancer Institute. Horseradish peroxidase-conjugated goat anti-mouse IgG was obtained from Pierce (Rockford, IL). Human Burkitt lymphoma CA46 cells were obtained from the American Type Culture Collection (Manassas, VA). These cells were used in all experiments, except as noted. A cellular volume of 0.651 μ l (Magrath et al., 1980) was used to calculate intracellular concentrations, with no correction made for nuclear volume. For analysis of p-gp 170 content in CA46 cells, two additional Burkitt lines were used as controls. These were the parental EW-36 line (Cherney et al., 1997) and the derived multidrug-resistant (MDR) line EW-36VCR60 (Mickley et al., 1998). Both lines were generously provided by Dr. T. Fojo, National Cancer Institute.

Cell Culture and Drug Transport Studies. In all experiments, cells were grown in suspension culture in RPMI-1640 medium supplemented with 10% fetal calf serum, 2 μ M L-glutamine, 10 μ g/ml gentamicin sulfate, and 0.1% (v/v) dimethyl sulfoxide (solvent for all drugs). Incubation was at 37° in a humidified 5% CO₂ atmosphere. For determination of IC_{50} values, an increase in cell number after 24 h was the parameter measured. In these studies, the initial inoculum was 3.5 to 4.0 \times 10⁵ cells/ml. Cell were grown in 25-cm² flasks containing 5 ml of medium.

The EW-36VCR60 cells were maintained in the same medium supplemented with 65 nM vincristine. One passage without vincristine was performed before using these cells for cytotoxicity experiments.

For the 24-h endpoint measurement of [3 H]dolastatin 10 or [3 H]vinblastine accumulation, cells were seeded at 1.4 \times 10⁵ cells/ml in 75 ml of medium in 75-cm² flasks. After 24 h, cell density was 3.2 \times 10⁵ cells/ml, and cells were treated with 50 pM [3 H]dolastatin 10 or 1.0 nM [3 H]vinblastine (the IC_{50} values; see below). After 24 h, cell suspensions were split into three aliquots, and cells were harvested in 50-ml polypropylene conical tubes by centrifugation for 5 min at 330g. Cells were resuspended in PBS (pH, 7.4) and recentrifuged. The supernatant was removed, and the bottom of each tube containing the cells was cut from the tube and placed in a scintillation vial. NaOH (0.5 ml of 0.5 M solution) was added to lyse the cells, followed 1 h later by 10 ml of scintillation cocktail.

Drug uptake kinetics was determined over 1-min, 2-h, and 24-h

periods. Cells (3.8 to 4.5 \times 10⁵ cells/ml) were treated with [3 H]dolastatin 10 or [3 H]vinblastine at the indicated concentrations. Cells were separated from medium by centrifugation through a cushion of silicone oil (Monks et al., 1985). A 13-ml aliquot of cell suspension was placed in a 15-ml polypropylene conical tube containing 1 ml of silicone oil (Versilube F50 from General Electric Silicone Products Division, Waterford, NY) and centrifuged at 3200g for 5 min at room temperature. Time points correspond to incubation times plus the time at which the centrifuge reached 100 to 150g (approximately 10 sec). The medium phase, the medium-oil interface, and most of the oil were removed sequentially. The bottom of the tube containing the cell pellet was cut and processed for counting as described. For time points up to 2 h, aliquots of cell suspension were incubated in tubes over oil. For longer time points, aliquots were withdrawn from the tissue culture flask, after even resuspension of the cells, and placed in tubes over oil shortly before centrifugation.

Drug efflux kinetics was determined over a 2-h period. Cells (4.9 \times 10⁵ cells/ml) were treated with 1.0 nM [3 H]dolastatin 10 or [3 H]vinblastine for 1 h in a 125 cm² flask (110-ml cell suspension). Cells were harvested by centrifugation and resuspended in fresh medium without drug. Aliquots (13 ml) were processed over silicone oil as described at the indicated time points.

ATP depletion was achieved by supplementing the medium with 15 mM NaN₃ and 50 mM 2-deoxy-D-glucose. For uptake experiments, cells were incubated for 15 min before treatment with 1.0 nM drug. For efflux experiments, drug-loaded cells were resuspended in the azide/2-deoxy-D-glucose-supplemented medium. For efflux experiments in the presence of verapamil, drug-loaded cells were resuspended in medium containing 10 μ M verapamil.

Cellular Tubulin Content. Cells were harvested by centrifugation, washed with PBS, and lysed for 30 min at 4° in a buffer containing 0.1 M 4-morpholineethanesulfonate (pH 6.6 with NaOH in 1 M stock solution), 20 μ g/ml aprotinin, 10 μ g/ml leupeptin, 100 μ g/ml phenylmethylsulfonyl fluoride, and 1% (v/v) NP-40. Extracts were centrifuged in an Eppendorf 5417C centrifuge at 14,000 rpm for 1 min at room temperature. The protein content of the supernatants was determined by the Lowry procedure. Tubulin in these extracts was quantitated with a competitive enzyme-linked immunosorbent assay method (Thrower et al., 1991). Purified bovine brain tubulin (Hamel and Lin, 1984) was used to coat 96-well, high-binding capacity microplates and was also used as the tubulin standard. For the coating procedure, 100 μ l of a tubulin solution at 6 μ g/ml was placed in each well, and the plate was left at room temperature for 1 h. For the generation of the standard tubulin curve, a tubulin solution at 0.2 mg/ml was used.

Cellular p-gp 170 Content. The Western blot technique was used to measure cellular p-gp 170 levels. Cell extracts were prepared as described for measuring tubulin content, except that the lysis buffer was the P-MER buffer obtained from Pierce supplemented with the protease inhibitor cocktail "Complete" obtained from and used as recommended by Boehringer-Mannheim. Extract proteins (40 μ g/lane) were electrophoresed on 8% acrylamide Tris-glycine polyacrylamide gels obtained from Novex (pH 8.6). Proteins were electrotransferred to a polyvinylidene difluoride membrane. The membrane was soaked for 1 h at room temperature in a solution containing Tris-buffered saline (25 mM Tris-HCl at pH 7.4, 137 mM NaCl, and 3 mM KCl; from Quality Biological), 0.1% Tween 20, and 5% dry milk (Solution A), followed by a brief wash in Tris-buffered saline containing 0.1% Tween 20 (Solution B). The membrane was incubated overnight at 4° in the primary C219 antibody directed against p-gp 170 (the stock antibody solution was diluted 1/5,000 in Solution A). The membrane was washed three times for 5 min in Solution B. The membrane was then incubated for 1 h at room temperature in Solution B containing horseradish peroxidase-conjugated secondary antibody (goat antimurine IgG) at a 1/50,000 dilution. The membrane was washed three times in Solution B for 5 min. The membrane was placed in chemiluminescent SuperSignal West Dura Extended Duration Signal solution for horseradish peroxidase

from Pierce for 5 min at room temperature. The membrane was exposed for 30 sec to Biomax-ML film from Kodak, as recommended by Pierce.

Results

Inhibition of CA46 Burkitt Lymphoma Cell Growth. In our initial studies we determined effects of the radiolabeled preparations of dolastatin 10 and vinblastine on the growth of CA46 Burkitt lymphoma cells. The [³H]dolastatin 10 was 20-fold more potent than the [³H]vinblastine. IC_{50} values for the two drugs were 50 ± 10 (S.D.; $n = 4$) pM and 1.0 ± 0.3 (S.D.; $n = 2$) nM, respectively, for inhibition of growth after a 24-h incubation. The values obtained for the nonradiolabeled drugs were identical, within experimental error.

Cellular Accumulation of [³H]dolastatin 10 and [³H]vinblastine. Our initial drug uptake study was measurement of intracellular drug content after 24 h of growth at the IC_{50} values (Table 1). Despite the 20-fold greater addition of vinblastine to the medium, virtually identical amounts of [³H]dolastatin 10 and [³H]vinblastine accumulated in the cells. Dolastatin 10 accumulated 19-fold more extensively than vinblastine, with only 3% of added vinblastine entering cells compared with 68% of the added dolastatin 10. This finding supports the idea that both drugs have the same intracellular target, assumedly tubulin (see *Discussion*), consistent with abundant morphological (mitotic arrest, disappearance of microtubules) and biochemical (effects on tubulin assembly etc.) observations.

Uptake Kinetics. On observing such extensive uptake of dolastatin 10 by the Burkitt cells, we hypothesized that it must have resulted from an active transport process, especially considering that the initial extracellular concentration was so low (50 pM). We also thought that the uptake of dolastatin 10 would be rapid. Studies of uptake kinetics and with cells depleted of ATP disproved both assumptions.

In the uptake kinetic studies, cells were pelleted through silicone oil before determination of cell-associated drug (Monks et al., 1985), in contrast with the initial direct centrifugation studies described above. Experiments at the IC_{50} values of dolastatin 10 and vinblastine were performed over a 24-h period (Fig. 1), and the results showed that dolastatin 10 uptake was far slower than that of vinblastine. The intracellular concentration of vinblastine had already reached an apparent maximum by 2 h, and the vinblastine concentration was substantially higher than the dolastatin 10 intracellular concentration at this time. In contrast, the dolastatin 10

concentration in cells increased over about 6 h before it, too, leveled off and then declined. In these experiments, the maximum concentration of vinblastine in the cells was 0.079 pmol/10⁶ cells at 2 h, with a decline to 0.044 pmol at the 24-h point. The maximum dolastatin 10 concentration in cells was 0.061 pmol/10⁶ cells at 6 h and declined to 0.031 pmol at 24 h. However, cell number was increasing during the experiment, and the percent drug in cells varied with time. The vinblastine in cells was 4.2% at 2 h and 2.4% at 24 h, and there was a somewhat smaller proportional decrease in the percentage of dolastatin 10 in the cells, from about 55% to 41%. This could indicate some cell lysis in these drug-treated cultures. Note that the 24-h values for intracellular drug were lower for both vinblastine and dolastatin 10 when the cells were pelleted through oil as opposed to harvested by direct centrifugation (Table 1). Usually this is interpreted to indicate removal of nonspecifically adherent drug. Possibly, however, the oil extracts drug specifically bound to membrane tubulin (Rubin et al., 1982), which could play a role in the cytotoxicity of these agents.

Drug uptake kinetics was next examined in detail over a 2-h period at the IC_{50} values, confirming the more rapid uptake of vinblastine, compared with dolastatin 10 (Fig. 2). Rapid vinblastine uptake has been reported for other cell lines (Gout et al., 1984; Ferguson and Cass, 1985; Pierre et al., 1992; El Hafny et al., 1997), but in some cases uptake of this drug is slow (cf. Van Belle et al., 1991). In our experiments, a plateau in intracellular vinblastine concentration was reached by 20 min, whereas there was a steady increase in the intracellular dolastatin 10 concentration over the 2-h time course. The actual difference in the uptake rates closely reflected the 20-fold difference in initial extracellular drug concentrations, with net uptake of vinblastine being 5.3 fmol/min/10⁶ cells versus 0.3 fmol/min/10⁶ cells for dolastatin 10 (rates measured between the 10- and 20-min time points).

Dolastatin 10 Uptake Is Not an Active Transport Process. Because the initial rate of dolastatin 10 uptake versus that of vinblastine seemed to reflect primarily the initial extracellular drug concentration, it seemed unlikely that an active transport process accounted for the more extensive intracellular accumulation of the peptide. Additional confirmation was obtained by examination of dolastatin 10 and vinblastine uptake at 1.0 nM and 50 pM, respectively, for comparison with the previous studies with dolastatin 10 at 50 pM and vinblastine at 1.0 nM. The data at the two concentrations of both drugs are presented in Fig. 3 as percentage of the added drug that enters cells over the first 2 h of

TABLE 1

Accumulation of dolastatin 10 or vinblastine in cells

Cells were treated for 24 h with 50 pM [³H]dolastatin 10 or 1.0 nM [³H]vinblastine (the IC_{50} values). Each experiment was performed twice, with triplicate values obtained with both drugs, except that the silicone oil experiment with vinblastine was performed three times.

Drug Added	Intracellular Drug pmol/10 ⁶ cells \pm S.D.	Intracellular Drug Concentration nM	Accumulation Factor ^a	Drug Initially Added to Medium in Cells
				%
Expt. I: Direct centrifugation				
Dolastatin 10	0.060 ^b	92	1840	68
Vinblastine	0.063 \pm 0.003	97	97	3.4
Expt. II: Centrifugation through oil				
Dolastatin 10	0.031 \pm 0.001	46	920	41
Vinblastine	0.044 \pm 0.01	61	61	2.4

S.D., standard deviation.

^aThe accumulation factor was calculated by dividing the intracellular drug concentration at 24 h by the initial concentration of the drug in the medium.

^bThe same value was obtained in both experiments.

incubation. For the first 15- to 20-min equivalent percentages of both drugs at both concentrations entered the cells, consistent with a diffusion-controlled mechanism. After 20 min, however, net additional accumulation of vinblastine was minimal, whereas that of dolastatin 10, at both concentrations, continued at virtually the same rate until the last time point.

An additional experiment further supported passive diffusion as the primary mode of drug entry into the Burkitt cells. Within a wider range of concentrations of both dolastatin 10 and vinblastine, there was no evidence for saturation of a transport mechanism (Fig. 4). When the rate of uptake of dolastatin 10 and vinblastine were measured within 90 sec of drug addition to cells at concentrations up to 10 nM, rate for both drugs varied only as a function of drug concentration.




Fig. 1. Uptake of dolastatin 10 (Δ) and vinblastine (\blacktriangle) over 24 h in Burkitt cells treated at the IC_{50} value for each drug. The initial media concentrations were 50 pM for [3 H]dolastatin 10 and 1.0 nM for [3 H]vinblastine. The dolastatin 10 experiment was performed twice and the vinblastine experiment three times (standard deviations indicated).




Fig. 2. Uptake of dolastatin 10 (Δ) and vinblastine (\blacktriangle) over 2 h in Burkitt cells treated at the IC_{50} value for each drug. The experiment was performed twice (standard deviations indicated).

The absence of an active transport mechanism for dolastatin 10 accumulation was additionally confirmed in an ATP depletion experiment, performed with drug at 1.0 nM (Fig. 5). Cells were pretreated with sodium azide and 2-deoxy-D-glucose for 15 min before drug addition. There was virtually no difference in uptake kinetics of dolastatin 10 from the kinetics observed without inhibitors of ATP generation. With vinblastine, however, intracellular drug concentration reached a modestly higher level than had occurred in the absence of azide and 2-deoxy-D-glucose. The difference may be within experimental error, but could also result from an ATP-dependent efflux of vinblastine (see below) that was inhibited by interfering with cellular production of ATP.

Efflux Kinetics. Cells were pretreated for 1 h with 1.0 nM [3 H]dolastatin 10 or [3 H]vinblastine, and drug efflux was followed (Fig. 6). The higher dolastatin 10 concentration was used to obtain sufficient radiolabel to follow in the efflux phase of the experiment, and we preferred a short treatment time to minimize effects because of poor viability of the cells. No efflux of dolastatin 10 was detected over the 2 h of the experiment, whereas almost 90% of the intracellular vinblastine was lost over the same period. After an initial lag of approximately 10 min, vinblastine efflux seemed to follow first-order kinetics for approximately 1 h, with a half-life of approximately 10 min. A similar rapid efflux of vinblastine has been reported for many cell lines (Lengsfeld et al., 1982; Gout et al., 1984; Ferguson and Cass, 1985; Pierre et al., 1992; El Hafny et al., 1997).

When cells were placed in ATP-depleting conditions for 2 h, after incubation for 1 h in the presence of radiolabeled drug




Fig. 3. Proportion of dolastatin 10 and vinblastine taken up over 2 h in Burkitt cells relative to the initial drug concentration in the medium. Symbols as follows: \circ , 50 pM [3 H]dolastatin 10; Δ , 1.0 nM [3 H]dolastatin 10; \square , 50 pM [3 H]vinblastine; ∇ , 1.0 nM [3 H]vinblastine. The experiments were performed twice, and the 50 pM dolastatin 10 data and 1.0 nM vinblastine data are the same data presented in Fig. 2.

at 1.0 nM, their retention of dolastatin 10 was unaffected, whereas there was a doubling in the retained vinblastine from about 9% to 18% of the level present before the efflux phase of the experiment (Table 2). Loss of vinblastine from the cells was minimally prevented by verapamil, and this agent was significantly less effective than the azide/2-deoxy-D-glucose treatment in preventing vinblastine loss (Table 2).

These findings with verapamil and azide/2-deoxy-D-glucose treatment made it very unlikely that the P-glycoprotein multidrug transporter (Gottesman and Pastan, 1993) was substantially involved in the loss of vinblastine from the CA46 Burkitt cells. To confirm this more directly, we examined the CA46 cells for expression of p-gp 170 in comparison with other Burkitt lines whose MDR status was well established (the negative EW-36 line and the highly positive EW-36VCR60 line [Mickley et al., 1998]). As shown in Fig. 7, the amounts of p-gp 170 in the CA46 and EW-36 lines were below detectable levels, whereas there was abundant p-gp 170 protein in the EW-36VCR60 line. For EW-36 cells the IC_{50} values obtained for vinblastine, vincristine, and dolastatin 10 were 4.0, 1.0, and 0.1 nM, respectively; and for EW-36VCR60 cells, 53, 248, and 0.4 nM (unpublished observations).

From these studies we conclude that the substantially higher proportion of added dolastatin 10 that accumulates in Burkitt cells as compared with vinblastine results from the absence of efflux of the peptide, whereas the intracellular vinca alkaloid concentration reaches an equilibrium based on passive diffusion, both into and out of the cells, combined with an active efflux process different from MDR-1.




Fig. 4. Initial uptake rates of [³H]dolastatin 10 (Δ) and [³H]vinblastine (\blacktriangle) by Burkitt cells as a function of initial drug concentration in the medium. For each data point the indicated drug concentration was added to cells suspended in medium and rapidly mixed without disturbing the silicone oil cushion, and the tube was centrifuged. Cells and drug in the medium were in contact for 60–90 sec. The experiment was performed three times (standard deviations indicated).

Discussion

We found that dolastatin 10 accumulated 15- to 19-fold more extensively than vinblastine at equitoxic concentrations (the IC_{50} values) in Burkitt lymphoma cells and therefore conclude that the 20-fold greater cytotoxicity of dolastatin 10 results from its more extensive intracellular accumulation. Because ATP depletion did not greatly affect uptake of either drug, their entry into cells probably results from passive diffusion through the plasma membrane. Supporting this, we found that the octanol/water partition coefficients for dolastatin 10 (1.4) and vinblastine (1.3) at physiological pH were nearly identical.

The major difference we observed between the drugs was a rapid efflux of vinblastine (Lengsfeld et al., 1982; Gout et al., 1984; Ferguson and Cass, 1985; Pierre et al., 1992; El Hafny et al., 1997) in contrast to no detectable efflux of dolastatin 10. Vinblastine efflux, additionally, was reduced under conditions of ATP depletion, suggesting involvement of an active mechanism. Verapamil had little effect on intracellular vinblastine, and p-gp 170 was not detected in the CA46 cells. Therefore, another unknown transport mechanism seems to be responsible for the apparent active efflux of vinblastine that we observed.

Dolastatin 10 and vinblastine, at their IC_{50} values, reached similar intracellular concentrations after 24 h, supporting the conclusion from morphological and biochemical findings that their intracellular target is tubulin. To define this more quantitatively, we measured total cellular protein in the Burkitt cells, obtaining a value of 62 pg of protein/cell, and determined that tubulin was 5.0% of cellular protein.




Fig. 5. ATP depletion has negligible effects on dolastatin 10 and vinblastine uptake by Burkitt cells. The medium contained the following: \circ , 1.0 nM [³H]dolastatin 10; ∇ , 1.0 nM [³H]vinblastine; \square , 1.0 nM [³H]dolastatin 10, NaN_3 , and 2-deoxy-D-glucose; or Δ , 1.0 nM [³H]vinblastine, NaN_3 , and 2-deoxy-D-glucose. The data without NaN_3 and 2-deoxy-D-glucose are the same as shown in Figs. 2 (vinblastine) and 3 (dolastatin 10), and the experiment with NaN_3 and 2-deoxy-D-glucose was performed three times. Standard deviations are indicated for all data.

Moreover, there was no decline in tubulin levels during 24 h of treatment with either vinblastine, in agreement with Jordan et al. (1991), or dolastatin 10 at the IC_{50} values. Taking cell volume as 0.651 μl (Magrath et al., 1980) and ignoring the nucleus, CA46 cells contain 48 μM total tubulin, so that approximately one molecule of dolastatin 10 or vinblastine for 500-1000 tubulin $\alpha\beta$ -dimers inhibits cell growth by 50%. Expressed another way, assuming 2/3 of tubulin is in polymer, the average microtubule is 5 μm in length (the cell radius), and each microtubule is anchored at the microtubule-organizing center, the concentration of microtubule (+)-ends in the untreated cell would be ~ 4 nM and tubulin at (+)-ends (13 protofilaments) ~ 50 nM. This is similar to intracellular concentrations of the drugs (50-100 nM) that we observed at the IC_{50} values and consistent with the hypothesis that interference with dynamic instability of microtubules rather than disassembly is primarily responsible for the inhibitory effects of microtubule depolymerizing agents

on cell growth (Wilson and Jordan, 1995). Furthermore, effects on dynamic instability by vinblastine in biochemical systems (Jordan and Wilson, 1990) and cells (Dhamodharan et al., 1995) have been observed at concentrations similar to the intracellular concentration we obtained at the IC_{50} value for CA46 cells.

We find vinblastine to be more potent than did Singer and Himes (1992), but our vinblastine:tubulin ratio is almost identical with that obtained from the data of Jordan et al. (1991). Singer and Himes (1992) derived an intracellular vinblastine concentration in B16 melanoma cells at the IC_{50} value from the accumulation factor determined at 1 μM drug (initial extracellular concentration) and concluded that at the IC_{50} value the B16 melanoma cells would have a vinblastine:tubulin ratio of about 1:150-200. Jordan et al. (1991) reported that the tubulin concentration of HeLa cells was 2.0 mg/ml and that near the IC_{50} value the intracellular vinblastine concentration was 38 nM, yielding a drug:tubulin ratio of 1:500.

Our comparison of dolastatin 10 and vinblastine suggests that equitoxic concentrations of microtubule assembly inhibitors in the culture medium lead to intracellular drug concentrations that have equivalent effects on the microtubule cytoskeleton and, consequently, on the fate of the cell. The study of Jordan et al. (1991) in HeLa cells with vinblastine and vincristine supports this concept. Vincristine and vinblastine do not show major differences in their interactions with tubulin (Himes, 1991), and, at initial extracellular drug concentrations close to the IC_{50} and IC_{90} values, intracellular drug concentrations were the same (30-40 and 150-160 nM, respectively). [The actual data (Jordan et al., 1991) follows. For vinblastine, the IC_{50} value was 0.45 nM and the extrapolated IC_{90} value was about 3 nM; for vincristine, 1.8 nM and about 7 nM, respectively. Jordan et al. (1991) reported 38 nM intracellular vinblastine with an initial extracellular concentration of 0.6 nM, and 33 nM intracellular vincristine with 1.8 nM extracellular drug. With 2.6 nM extracellular vinblastine, the intracellular concentration was 152 nM; with 10 nM extracellular vincristine, the intracellular drug was 163 nM.]

What accounts for the dramatic retention of dolastatin 10 as compared with vinblastine by CA46 cells? The difference in cellular accumulation can be explained in terms of the interactions of the two drugs with tubulin. Although their quantitative effects on assembly reactions are similar, there are major differences in their binding to tubulin and/or aberrant tubulin polymers. With both drugs it is difficult to document binding to the $\alpha\beta$ -tubulin dimer in the absence of an associated formation of spiral polymers. Both polymers




Fig. 6. Dolastatin 10, but not vinblastine, is tenaciously retained by Burkitt cells. Cells were preloaded with radiolabeled drug during a 1-h incubation with either 1.0 nM [³H]dolastatin 10 (Δ) or 1.0 nM [³H]vinblastine (\blacktriangle). Cells were harvested by centrifugation and resuspended in media without drug. At the indicated times, cells in aliquots of each reaction mixture were centrifuged through oil. The experiment was performed three times (standard deviations indicated).

TABLE 2

Effect of ATP depletion and verapamil on efflux of dolastatin 10 and vinblastine from Burkitt CA46 cells
The % relative to value before efflux phase is shown in parentheses.

Drug	Before Efflux Phase ^a	No Addition ^b	<i>pmol drug/10⁶ cells \pm S.D.^c</i>	
			+ NaN ₃ /2dG ^c	+ Verapamil ^d
Dolastatin 10	0.27 \pm 0.04 (100)	0.28 \pm 0.01 (104)	0.28 \pm 0.03 (104)	0.30 \pm 0.05 (111)
Vinblastine	0.028 \pm 0.006 (100)	0.0026 \pm 0.002 (9.3)	0.0050 \pm 0.003 (18)	0.0035 \pm 0.002 (18)

S.D., standard deviation.

^a Cells were incubated for 1 h in medium containing 1.0 nM [³H]dolastatin 10 or [³H]vinblastine. Aliquots were removed, and the cells were centrifuged through silicone oil to obtain the values shown in this column. For the efflux phase of the experiment, the remainder of each culture was divided into three portions, with the cells harvested by centrifugation.

^b Cells were resuspended in medium and incubated for 2 h. Cells were harvested by centrifugation through silicone oil.

^c Cells were resuspended in medium containing NaN₃ and 2-deoxy-D-glucose (2dG) and incubated for 2 h. Cells were harvested by centrifugation through silicone oil.

^d Cells were resuspended in medium containing verapamil and incubated for 2 h. Cells were harvested by centrifugation through silicone oil.

^e The experiment was performed twice, and in each experiment data points were based on triplicate samples.

and smaller oligomeric intermediates can be resolved from heterodimer on HPLC gel permeation columns, but preservation of vinblastine-induced structures requires drug in the column equilibration buffer (Singer et al., 1988). Preservation of dolastatin 10-induced structures does not require drug in the column buffer (Bai et al., 1995), and an unbound dolastatin 10 peak only appeared when drug:tubulin > 1.0. Moreover, the apparent K_a value obtained for dolastatin 10 ($3.8 \times 10^7 \text{ M}^{-1}$; Bai et al., 1995) is 21-fold higher than that obtained for vinblastine ($1.8 \times 10^6 \text{ M}^{-1}$; Safa et al., 1987) under comparable reaction conditions. [Literature values for the apparent K_a for vinblastine vary from 2×10^4 to $6 \times 10^6 \text{ M}^{-1}$, and the variation seems to depend primarily on reaction conditions (Himes, 1991).] This difference in apparent K_a values is almost identical with the difference in the accumulation factors obtained at 24 h.

The much more rapid uptake of vinblastine compared with dolastatin 10 suggested that cell kill with the vinca alkaloid would require a shorter treatment time, although vinblastine efflux after medium exchange or possible differences in minimum drug exposure time for onset of apoptosis (cf. Mooberry et al., 1997) could complicate data interpretation. Other lymphoma cell lines showed irreversible cytotoxicity after 4–8 h of exposure to dolastatin 10 (Beckwith et al., 1993), in good agreement with our observation that maximum uptake of the peptide at its IC_{50} value occurred at 6 h. When we examined drug exposure time for the Burkitt cells at the IC_{90} values (determined from the 24-h continuous exposure studies), we found that 4 h of exposure to dolastatin 10 and 24 h of exposure to vinblastine were required for maximum effects on subsequent cell growth (data not presented). Thus, differences in efflux and uptake rates between the two drugs, together with difference in the strength of their interactions with tubulin, probably play roles in the rapidity with which they kill cells. Our data suggest that for clinical studies dolastatin 10 would be optimally delivered as a slow infusion over several hours rather than by bolus administration, and that still longer infusion times would enhance the efficacy of vinblastine.

The depsipeptides cryptophycins 1 and 52 have many similarities to dolastatin 10 in their effects on tubulin, including formation of structures stable to gel filtration (Kerksiek et al., 1995; Bai et al., 1996; Smith and Zhang, 1996; Moore, 1997). For Burkitt CA46, EW-36, and EW-36VCR60 cells we obtained IC_{50} values, respectively, of 20, 12, and 13 pM for cryptophycin 1 (unpublished observations). Cryptophycin 52 has been reported to be similar to cryptophycin 1 in its interactions with cells and tubulin (Moore, 1997). One would therefore predict similar findings to those reported here for dolastatin 10, and there have been two recent cellular uptake

studies with cryptophycin 52 (Chen et al., 1998; Panda et al., 1998).

Chen et al. (1998), using a very high cryptophycin 52 concentration (1.5 μM) in a leukemia cell line, observed no detectable drug efflux (similar to our finding), maximal uptake by 20 min (versus the 6 h we found for dolastatin 10), and saturable uptake, suggesting an active transport process (opposite to our finding with dolastatin 10 concentrations up to 10 nM).

Panda et al. (1998), studying HeLa cells treated with 11 pM cryptophycin 52, the IC_{50} value, found that the intracellular drug concentration at 20 h was 8 nM, with an accumulation factor of 730 (somewhat lower than we found with dolastatin 10). Because the 2.0 mg/ml tubulin content of HeLa cells (Jordan et al., 1991) is less than half that of Burkitt cells, the data of Panda et al. (1998) yield a drug:tubulin ratio of 1:2500 at the IC_{50} value, 2.5 to 5-fold lower than our ratio for dolastatin 10 and 3- to 5-fold lower than our ratio for vinblastine. Panda et al. (1998) interpreted their results in terms of an exceptionally tight binding of cryptophycin 52 to microtubule ends with consequent inhibition of dynamic instability. A direct comparison of dolastatin 10 with cryptophycin 52 should provide additional insights into the mechanism of action of these potent peptide antimitotic drugs.

References

Bagniewski PG, Reid JM, Pitot HC, Sloan JA and Ames MM (1997) Pharmacokinetics of dolastatin 10 in adult patients with solid tumors. *Proc Am Assoc Cancer Res* 38:221–222.

Bai R, Friedman SJ, Pettit GR and Hamel E (1992) Dolastatin 15, a potent antimitotic depsipeptide derived from *Dolabella auricularia*: Interaction with tubulin and effects on cellular microtubules. *Biochem Pharmacol* 43:2637–2645.

Bai R, Pettit GR and Hamel E (1990a) Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. *J Biol Chem* 265:17141–17149.

Bai R, Pettit GR and Hamel E (1990b) Dolastatin 10, a powerful cytostatic peptide derived from a marine animal: Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. *Biochem Pharmacol* 39:1941–1949.

Bai R, Schwartz RE, Kepler JA, Pettit GR and Hamel E (1996) Characterization of the interaction of cryptophycin 1 with tubulin: Binding in the Vinca domain, competitive inhibition of dolastatin 10 binding, and an unusual aggregation reaction. *Cancer Res* 56:4398–4406.

Bai R, Taylor GF, Schmidt JM, Williams MD, Kepler JA, Pettit GR and Hamel E (1995) Interaction of dolastatin 10 with tubulin: Induction of aggregation and binding and dissociation reactions. *Mol Pharmacol* 47:965–976.

Beckwith M, Urba WJ and Longo DL (1993) Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15. *J Natl Cancer Inst* 85:483–488.

Breier A, Stefankova Z, Barancik M and Tribulova N (1994) Time dependence of [³H]-vincristine accumulation by L1210 mouse leukemic cells: Effect of P-glycoprotein overexpression. *Gen Physiol Biophys* 13:287–298.

Chen BD-M, Nakoff A and Valeriote F (1998) Cellular uptake of a novel cytotoxic agent, cryptophycin 52, by human THP-1 leukemia cells and H-125 lung tumor cells. *Int J Cancer* 77:869–873.

Cherney BW, Bhatia KG, Sgadari C, Gutierrez MI, Mostowski H, Pike SE, Gupta G, McGrath IT and Tosato G (1997) Role of the p53 tumor suppressor gene in the tumorigenicity of Burkitt's lymphoma cells. *Cancer Res* 57:2508–2515.

Dhamodharan R, Jordan MA, Thrower D, Wilson L and Wadsworth P (1995) Vinblastine suppresses dynamics of individual microtubules in living interphase cells. *Mol Biol Cell* 6:1215–1229.

El Hafny B, Cano N, Piciotti M, Regina A, Scherrmann J-M and Roux F (1997) Role of P-glycoprotein in colchicine and vinblastine cellular kinetics in an immortalized rat brain microvessel endothelial cell line. *Biochem Pharmacol* 53:1735–1742.

Ferguson PJ and Cass CE (1985) Differential cellular retention of vincristine and vinblastine by cultured human promyelocytic leukemia HL-60/Cl cells: The basis of differential cytotoxicity. *Cancer Res* 45:5480–5488.

Gottesman MM and Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. *Annu Rev Biochem* 62:385–427.

Gout PW, Noble RL, Bruchovsky N and Beer CT (1984) Vinblastine and vincristine: Growth inhibitory effects correlate with their retention by cultured Nb 2 node lymphoma cells. *Int J Cancer* 34:245–248.

Hamel E and Lin CM (1984) Separation of active tubulin and microtubule-associated proteins by ultracentrifugation and isolation of a component causing the formation of microtubule bundles. *Biochemistry* 23:4173–4184.

Himes RH (1991) Interactions of the *Catharanthus* (Vinca) alkaloids with tubulin and microtubules. *Pharmacol Ther* 51:257–267.

Jordan MA, Thrower D and Wilson L (1991) Mechanism of inhibition of cell proliferation by Vinca alkaloids. *Cancer Res* 51:2212–2222.

Jordan MA and Wilson L (1990) Kinetic analysis of tubulin exchange at microtubule ends at low vinblastine concentrations. *Biochemistry* 29:2730–2739.




Fig. 7. Expression of p-gp 170 in CA46, EW-36, and EW-36VCR60 Burkitt cell lines. Equal amounts (40 μg) of total cell extract from each cell line was loaded onto the polyacrylamide gel. Western blot analysis for p-gp 170 was performed with the monoclonal antibody C219 as described in detail in the text.

Kerksiek K, Mejillano MR, Schwartz RE, Georg GI and Himes RH (1995) Interaction of cryptophycin 1 with tubulin and microtubules. *FEBS Lett* 377:59–61.

Lengsfeld AM, Dietrich J and Schultze-Maurer B (1982) Accumulation and release of vinblastine and vincristine by HeLa cells: Light microscopic, cinematographic, and biochemical study. *Cancer Res* 42:3798–3805.

Magrath IT, Pizzo PA, Whang-Peng J, Douglass EC, Alabaster O, Gerber P, Freeman CB and Novikovs L (1980) Characterization of lymphoma-derived cell lines: comparison of cell lines positive and negative for Epstein-Barr virus nuclear antigen. I. Physical, cytogenetic, and growth characteristics. *J Natl Cancer Inst* 64:465–473.

Mickley LA, Lee SJ, Weng Z, Zhan Z, Alvarez M, Wilson W, Bates SE and Fojo T (1998) Genetic polymorphism in MDR-1: A tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. *Blood* 91:1749–1756.

Monks A, Marquez VA, Mao DT and Cysyk RL (1985) Uptake of 2- β -D-ribosuranothiazole-4-carboxamide (tiazofurin) and analogues by the facilitated transport mechanism of erythrocytes. *Cancer Lett* 28:1–8.

Mooberry SL, Busquets L and Tien G (1997) Induction of apoptosis by cryptophycin 1, a new antimicrotubule agent. *Int J Cancer* 73:440–448.

Moore RE (1997) Presentation at the Fourth Anticancer Drug Discovery and Development Symposium; Aug 4–6, 1997; Annapolis, MD.

Panda D, DeLuca K, Williams D, Jordan MA and Wilson L (1998) Antiproliferative mechanism of action of cryptophycin-52: Kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends. *Proc Natl Acad Sci USA* 95:9313–9318.

Pettit GR, Kamano Y, Herald CL, Tuinman AA, Boettner FE, Kizu H, Schmidt JM, Baczyński L, Tomer KB and Bontems RJ (1987) The isolation and structure of a remarkable marine animal antineoplastic constituent: Dolastatin 10. *J Am Chem Soc* 109:6883–6885.

Pettit GR, Singh SB, Hogan F, Lloyd-Williams P, Herald DL, Burkett DD and Clewlow PJ (1989) The absolute configuration and synthesis of natural (–)-dolastatin 10. *J Am Chem Soc* 111:5463–5465.

Pierre A, Perez V, Leonce S, Boutin JA, Saint-Dizier D, Hautefaye P, Lavielle G and Atassi G (1992) Relationship between the cellular accumulation and the cytotoxicity of S12363, a new Vinca alkaloid derivative. *Cancer Chemother Pharmacol* 29:367–374.

Rubin RW, Quillen M, Corcoran JJ, Ganapathi R and Krishan A (1982) Tubulin as a major cell surface protein in human lymphoid cells of leukemic origin. *Cancer Res* 42:1384–1389.

Safa AR, Hamel E and Felsted RL (1987) Photoaffinity labeling of tubulin subunits with a photoactive analogue of vinblastine. *Biochemistry* 26:97–102.

Singer WD, Hersh RT and Himes RH (1988) Effect of solution variables on the binding of vinblastine to tubulin. *Biochem Pharmacol* 37:2691–2696.

Singer WD and Himes RH (1992) Cellular uptake and tubulin binding properties of four vinca alkaloids. *Biochem Pharmacol* 43:545–551.

Smith CD and Zhang X (1996) Mechanism of action of cryptophycin: Interaction with the Vinca alkaloid domain of tubulin. *J Biol Chem* 271:6192–6198.

Thrower D, Jordan MA and Wilson L (1991) Quantitation of cellular tubulin in microtubules and tubulin pools by a competitive ELISA. *J Immunol Methods* 136:45–51.

Turner T, Jackson WH, Pettit GR, Wells A and Kraft AS (1998) Treatment of human prostate cancer cells with dolastatin 10, a peptide isolated from a marine shell-less mollusc. *Prostate* 34:175–181.

Van Belle SJ, De Smet MC, De Mey JE and Storme GA (1991) Cellular pharmacokinetics of vinblastine and other vinca alkaloids in MO4 cells. *Anticancer Res* 11:465–471.

Waud WR, Dykes DJ, Pettit GR and Plowman J (1993) Preclinical antitumor activity of dolastatin 10. *Proc Am Assoc Cancer Res* 34:383.

Wilson L and Jordan MA (1995) Microtubule dynamics: Taking aim at a moving target. *Chem Biol* 2:569–573.

Send reprint requests to: Dr. E. Hamel, P. O. Box B, Building 469, Room 237, NCI-Frederick Cancer Research and Development Center, Frederick, Maryland 21702. E-mail: hamele@dc37a.nci.nih.gov